Sam Moussa

No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease

Joseph A. Murray, Ciarán P. Kelly, Peter H.R. Green et al. · Gastroenterology · 2016 · 131 citations · Full text

Difference Between Latiglutenase, Villous Atrophy, Clinical Presentation +3

MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study

Stephen A. Harrison, Sam Moussa, Mustafa R. Bashir et al. · Journal of Hepatology · 2018 · 34 citations

Obesity, Metabolic Syndrome, Body Composition +15

Primary results from MAESTRO-NASH a pivotal phase 3 52-week serial liver biopsy study in 966 patients with NASH and fibrosis

Stephen A. Harrison, Pierre Bédossa, Cynthia D. Guy et al. · Journal of Hepatology · 2023 · 22 citations

Fibrosis, Hepatology, Primary Results +12

Primary data analyses of MAESTRO-NAFLD-1 a 52 week double-blind placebo-controlled phase 3 clinical trial of resmetirom in patients with NAFLD

Stephen A. Harrison, Rebecca Taub, Guy Neff et al. · Journal of Hepatology · 2022 · 13 citations

Symptomatic Treatment, Clinical Trials, Pharmacologic Intervention +2